Last reviewed · How we verify
Efavirenz + 2 NRTIs
Efavirenz inhibits HIV reverse transcriptase while the two NRTIs (nucleoside reverse transcriptase inhibitors) act as chain terminators to block viral replication.
Efavirenz inhibits HIV reverse transcriptase while the two NRTIs (nucleoside reverse transcriptase inhibitors) act as chain terminators to block viral replication. Used for HIV-1 infection (treatment-naive patients).
At a glance
| Generic name | Efavirenz + 2 NRTIs |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Antiretroviral combination therapy (NNRTI + 2 NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
This is a combination antiretroviral regimen used in HIV treatment. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase and blocks its activity. The two NRTIs (typically lamivudine and zidovudine or tenofovir) are nucleoside analogs that get incorporated into the growing viral DNA chain, causing chain termination and preventing viral replication. Together, they provide synergistic suppression of HIV.
Approved indications
- HIV-1 infection (treatment-naive patients)
Common side effects
- Dizziness and CNS effects
- Rash
- Nausea
- Headache
- Lipid abnormalities
- Hepatotoxicity
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Dolutegravir in Pregnant HIV Mothers and Their Neonates (PHASE3)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children (PHASE1)
- Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: